ARKK Holdings of EDIT
Editas Medicine
EDIT, or Editas Medicine, is a pioneering company in the field of genome editing, focusing on developing transformative therapies using CRISPR technology to treat a range of genetic disorders. It generates revenue through collaborative development agreements and potential future sales of its bespoke gene-editing treatments.
Trades of EDIT in ARKK
The ten most recent trades of Editas Medicine in the ARKK ETF.View all trades
Date | Direction | Market Value | % of Position | % of ETF |
|---|---|---|---|---|
| Feb 03, 2022 | Sell | $28,522 | 100.00% | 0.00% |
| Feb 01, 2022 | Sell | $1,317,405 | 4,146.43% | 0.01% |
| Jan 31, 2022 | Sell | $1,463,091 | 114.23% | 0.01% |
| Jan 27, 2022 | Sell | $1,529,806 | 57.11% | 0.01% |
| Jan 26, 2022 | Sell | $22,855,895 | 524.37% | 0.19% |
| Jan 25, 2022 | Sell | $2,066,999 | 7.67% | 0.02% |
| Jan 24, 2022 | Sell | $4,043,988 | 14.76% | 0.03% |
| Jan 21, 2022 | Sell | $5,792,445 | 17.15% | 0.05% |
| Jan 20, 2022 | Sell | $3,173,918 | 7.61% | 0.03% |
| Jan 19, 2022 | Sell | $3,794,176 | 8.45% | 0.03% |